A Phase II Study of PHA-739358 in Patients With Metastatic Hormone Refractory Prostate Cancer
A Phase II Study of PHA-739358 in Patients With Metastatic Hormone Refractory Prostate Cancer
To assess the antitumor activity of PHA-739358 administered as IV infusion according to two different dose schedules in metastatic HRPC patients progressing on standard, docetaxel-based 1st-line chemotherapy for HRPC based on PSA response, and to select the best dose schedule for further investigation.
Inclusion Criteria:
Exclusion Criteria: